- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04592861
Carbon Ion RT for Locally Advanced Pancreatic Cancer
January 2, 2024 updated by: Albert Einstein College of Medicine
A Prospective, Randomized, Phase 3 Trial of Carbon Ion Radiation Therapy Versus Standard Care for Locally Advanced Pancreatic Cancer
This is an open-label randomized trial.
Subjects will be randomized in a 2:1 ratio to receive carbon ion radiotherapy versus standard care for locally advanced pancreatic cancer.
Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians.
Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
Subjects on the control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon ion radiotherapy) if disease progression occurs.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201315
- Shanghai Proton and Heavy Ion Center (SPHIC)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically or cytologically proven diagnosis of adenocarcinoma of the pancreas
- Sum of maximum diameters of tumor and involved lymph nodes ≤6 cm T1-4N0-1M0,
- Unresectable disease by radiographic criteria (pancreas protocol CT or MRI) or surgical exploration within 30 days prior to registration, defined based on at least one of the following:
major venous thrombosis of the portal vein or SMV extending for several centimeters (precluding vein resection and reconstruction) encasement (>180°) of the SMA or proximal hepatic artery abutment of the celiac trunk
- No evidence of distant metastases, based upon axial (PET, CT, or MRI) imaging of the chest, abdomen, and pelvis within 30 days prior to registration
- ECOG Performance Status 0-1 within 30 days prior to registration
- Age ≥ 18
- CBC/differential obtained within 14 days prior to step 1 registration, with adequate bone marrow function defined as follows:
- Absolute neutrophil count (ANC) ≥ 1,500 cells/mm3
- Platelets ≥ 100,000 cells/mm3
- Hemoglobin ≥ 9.0 g/dl (NOTE: The use of transfusion or other intervention to achieve Hgb ≥ 9.0 g/dl is acceptable)
- Additional laboratory studies within 14 days prior to registration demonstrating:
Creatinine < 2 mg/dl; GFR > 50 mL/min (Cockroft and Gault formula)
- Bilirubin < 1.5 x ULN
- ALT and AST ≤ 2.5 x ULN
- aPTT, PT ≤ 1.5 x ULN
- Patients must provide study specific informed consent prior to study entry.
- Women of childbearing potential and male participants must practice adequate contraception during protocol treatment and for at least 6 months following treatment For females of child-bearing potential, negative serum pregnancy test within 30 days prior to registration
Exclusion Criteria:
- More than one primary lesion
- Tumor invasion of the duodenum or stomach, confirmed by upper endoscopy
- Active malignancy, other than pancreatic cancer, for which systemic therapy is indicated. -History of adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy asides from hormonal therapy, adequately treated stage 1or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for ≥ 5 years is permitted.
- Prior treatment for pancreatic cancer with surgical resection, external radiotherapy, or interstitial isotope implantation.
- Prior treatment for pancreatic cancer with a systemic therapy regimen/agent not included in the list below. Systemic therapy must be discontinued at least 14 days before study enrollment.
- FOLFIRINOX
- Gemcitabine/nab-paclitaxel
- Gemcitabine
- S-1
- Prior radiation therapy to the abdomen that would result in overlap of radiation therapy fields
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Carbon ion radiotherapy
Carbon ion radiotherapy will be administered 5 days each week (Monday-Friday).
The prescription dose will be 60 GyE in 20 fractions, to be delivered over four weeks.
|
daily carbon ion radiotherapy
Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians.
Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
|
Active Comparator: Routine standard of care
Subjects on the control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon ion radiotherapy) if disease progression occurs.
|
Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians.
Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival duration
Time Frame: The length of time from randomization until death from any cause for up to 24 months
|
The length of time from randomization of treatment for cancer, that patients diagnosed with the disease are still alive.
|
The length of time from randomization until death from any cause for up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival duration
Time Frame: he length of time from study registration until disease progression at any site or death from any cause, up to 24 months
|
The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
|
he length of time from study registration until disease progression at any site or death from any cause, up to 24 months
|
Local disease progression scored using RECIST 1.1 criteria
Time Frame: Up to 24 months
|
A set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment
|
Up to 24 months
|
Adverse events as defined by CTCAE v5.0
Time Frame: Up to 24 months
|
A set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy.
|
Up to 24 months
|
Quality-of-life, measured using the EORTC (European Organisation for Research and Treatment of Cancer) QLQ-C30 questionnaire
Time Frame: up to 24 months
|
Questionnaire developed to measure the quality of life of cancer patients.
Composite scores range from 0 to 100, with higher scores being more favorable.
|
up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Nitin Ohri, MD, Associate Professor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2020
Primary Completion (Actual)
August 24, 2022
Study Completion (Actual)
August 24, 2022
Study Registration Dates
First Submitted
September 11, 2020
First Submitted That Met QC Criteria
October 13, 2020
First Posted (Actual)
October 19, 2020
Study Record Updates
Last Update Posted (Actual)
January 5, 2024
Last Update Submitted That Met QC Criteria
January 2, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-11511
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Fudan UniversityUnknownStage ⅠA Pancreatic Cancer | Stage ⅠB Pancreatic Cancer | Stage ⅡA Pancreatic Cancer | Stage ⅡB Pancreatic CancerChina
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
Clinical Trials on carbon ion RT
-
Shanghai Proton and Heavy Ion CenterRecruitingLocalized Prostate CancerChina
-
University Hospital HeidelbergRecruiting
-
Heidelberg UniversityRecruitingChordoma | Tumor | TreatmentGermany
-
University Hospital HeidelbergActive, not recruiting
-
University Hospital HeidelbergCompletedRecurrent Rectal CancerGermany
-
University Hospital HeidelbergWithdrawnLocally Advanced Pancreatic CancerGermany
-
Shanghai Proton and Heavy Ion CenterRecruiting
-
Shanghai Proton and Heavy Ion CenterRecruitingPancreatic Cancer Non-resectableChina
-
Shanghai Proton and Heavy Ion CenterRecruitingProstate Cancer | RadiotherapyChina
-
Shanghai Proton and Heavy Ion CenterRecruiting